Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O14791
UPID:
APOL1_HUMAN
Alternative names:
Apolipoprotein L; Apolipoprotein L-I
Alternative UPACC:
O14791; A5PLQ4; B4DU12; E9PF24; O60804; Q5R3P7; Q5R3P8; Q96AB8; Q96PM4; Q9BQ03
Background:
Apolipoprotein L1 (ApoL1), with alternative names Apolipoprotein L and Apolipoprotein L-I, plays a crucial role in lipid transport and metabolism. It is instrumental in reverse cholesterol transport, a vital process for maintaining cellular cholesterol homeostasis.
Therapeutic significance:
ApoL1 is linked to Focal segmental glomerulosclerosis 4, a renal disease characterized by glomeruli damage and progressive renal failure. Understanding ApoL1's function and its genetic variants offers a pathway to novel treatments for this condition.